Marinomed Biotech AG (VIE:MARI)

Market Cap	19.99M -20.0%
Revenue (ttm)	7.96M +66.1%
Net Income	18.02M
EPS	9.79
Shares Out	2.00M
PE Ratio	1.02
Forward PE	6.71
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,718
Average Volume	6,748
Open	10.00
Previous Close	10.00
Day's Range	9.50 - 10.00
52-Week Range	8.60 - 21.00
Beta	-0.16
RSI	28.50
Earnings Date	Apr 22, 2026

About Marinomed Biotech AG

Marinomed Biotech AG, a biopharmaceutical company, develops therapeutic products for indications in virology and immunology in Austria, other European countries, and internationally. Its products pipeline includes Budesolv for the treatment of allergic rhinitis and autoimmune gastritis; Tacrosolv, which is in Phase II clinical trial for anterior inflammatory eye diseases; Carravin for the treatment of nasal congestion; and Inhaleen that is in Phase I clinical trial for viral pneumonia, as well as Carragelose, which consists of nasal and throat ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2006
• Employees: 32
• Stock Exchange: Vienna Stock Exchange
• Ticker Symbol: MARI